Skip to Content

Abivax SA - Stock Quote ABVX

Rating as of

Morningstar's Abivax SA Stock Analysis

Currency in EUR
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Abivax SA's Company Profile

Business Description

Abivax SA is a France based biotechnology company. It is focused on using antiviral technology platform targeting the immune system to eliminate viral diseases. The company's product is ABX 464 which is for treating HIV/AIDS. The antiviral and immunotherapeutic products that the group develops result from three technology platforms; an Antiviral platform, an Immune stimulation platform, and a Polyclonal antibody platform. The Antiviral platform targets the formation of Ribonucleoprotein's in the nucleus or the cytoplasm of the infected cell during viral infection, Immune stimulation platform focuses on invariant natural killer agonists and Polyclonal antibodies platform generates neutralizing antibodies against different viruses.

5, Rue de la Baume
Paris, 75008, France
T +33 153830841
Sector Healthcare
Industry Biotechnology
Most Recent Earnings
Fiscal Year End Dec 31, 2020
Stock Type
Employees 24